+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Multiple Sclerosis Drugs Market 2020-2027

  • ID: 5397820
  • Report
  • July 2021
  • Region: Global
  • 163 Pages
  • GMD Research

FEATURED COMPANIES

  • Abbvie, Inc.
  • Acorda Therapeutics Inc.
  • Bayer AG
  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck KgaA

Global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs.





Highlighted with 87 tables and 87 figures, this 163-page report “Global Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Region: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire global multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year because 2020 is not appropriate for research base due to the outbreak of COVID-19.



In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Five Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Region.



Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.


Immunomodulators


  • Copaxone
  • Avonex/Plegridy
  • Gilneya
  • Tysabri
  • Betaseron/Extavia
  • Tecifidera
  • Rebif
  • Ampyra
  • Other Immunomodulators

Immunosuppressants


  • Aubagio
  • Lemtrada
  • Ocrelizumab
  • Zinbryta
  • Other Immunosuppressants

Based on Drug Class, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.

  • Monoclonal Antibodies
  • Interferon Beta
  • Sphingosine 1 Phosphate Receptor Modulators
  • Mixed Polymers
  • NF-?B Inhibitor
  • Pyrimidine Synthesis Inhibitor
  • Corticosteroids
  • Adrenocorticotropic Hormone
  • Other Drug Classes

Based on Drug Category, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.

  • Large-molecule Drugs
  • Small-molecule Drugs

Based on Route of Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.

  • Oral Administration
  • Parenteral Administration

Based on MS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.

  • Relapsing-remitting MS (RRMS)
  • Primary-progressive MS (PPMS)
  • Secondary-progressive MS (SPMS)
  • Progressive-relapsing MS (PRMS)

Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Geographically, the following regions together with the listed national/local markets are fully investigated:

  • North America (U.S., Canada, and Mexico)
  • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
  • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
  • South America (Brazil, Chile, Argentina, Rest of South America)
  • MEA (UAE, Saudi Arabia, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included.



The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.



Key Players (this may not be a complete list and extra companies can be added upon request):

  • Abbvie, Inc.
  • Acorda Therapeutics Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck KgaA
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)


Frequently Asked Questions about the Global Multiple Sclerosis Drugs Market

What is the estimated value of the Global Multiple Sclerosis Drugs Market?

The Global Multiple Sclerosis Drugs Market was estimated to be valued at $22288.6 Million in 2020.

What is the growth rate of the Global Multiple Sclerosis Drugs Market?

The growth rate of the Global Multiple Sclerosis Drugs Market is 4.3%, with an estimated value of $29971.4 Million by 2027.

What is the forecasted size of the Global Multiple Sclerosis Drugs Market?

The Global Multiple Sclerosis Drugs Market is estimated to be worth $29971.4 Million by 2027.

Who are the key companies in the Global Multiple Sclerosis Drugs Market?

Key companies in the Global Multiple Sclerosis Drugs Market include Abbvie, Inc., Acorda Therapeutics Inc., Bayer AG, Biogen Inc., Bristol, Myers Squibb Company, F. Hoffmann, La Roche Ltd. and Mylan NV.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie, Inc.
  • Acorda Therapeutics Inc.
  • Bayer AG
  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck KgaA

1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Five Forces Analysis
3 Segmentation of Global Market by Drug Type
3.1 Market Overview by Drug Type
3.2 Immunomodulators
3.3 Immunosuppressants
4 Segmentation of Global Market by Drug Class
4.1 Market Overview by Drug Class
4.2 Monoclonal Antibodies
4.3 Interferon Beta
4.4 Sphingosine 1 Phosphate Receptor Modulators
4.5 Mixed Polymers
4.6 NF-?B Inhibitor
4.7 Pyrimidine Synthesis Inhibitor
4.8 Corticosteroids
4.9 Adrenocorticotropic Hormone
4.10 Other Drug Classes
5 Segmentation of Global Market by Drug Category
5.1 Market Overview by Drug Category
5.2 Large-molecule Drugs
5.3 Small-molecule Drugs
6 Segmentation of Global Market by Route of Administration
6.1 Market Overview by Route of Administration
6.2 Oral Administration
6.3 Parenteral Administration
7 Segmentation of Global Market by MS Type
7.1 Market Overview by MS Type
7.2 Relapsing-remitting MS (RRMS)
7.3 Primary-progressive MS (PPMS)
7.4 Secondary-progressive MS (SPMS)
7.5 Progressive-relapsing MS (PRMS)
8 Segmentation of Global Market by Distribution Channel
8.1 Market Overview by Distribution Channel
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
9 Segmentation of Global Market by Region
9.1 Geographic Market Overview 2020-2027
9.2 North America Market 2020-2027 by Country
9.2.1 Overview of North America Market
9.2.2 U.S.
9.2.3 Canada
9.2.4 Mexico
9.3 European Market 2020-2027 by Country
9.3.1 Overview of European Market
9.3.2 UK
9.3.3 France
9.3.4 Germany
9.3.5 Spain
9.3.6 Italy
9.3.7 Russia
9.3.8 Rest of European Market
9.4 Asia-Pacific Market 2020-2027 by Country
9.4.1 Overview of Asia-Pacific Market
9.4.2 China
9.4.3 Japan
9.4.4 India
9.4.5 Australia
9.4.6 South Korea
9.4.7 Rest of APAC Region
9.5 South America Market 2020-2027 by Country
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America Market
9.6 MEA Market 2020-2027 by Country
9.6.1 UAE
9.6.2 Saudi Arabia
9.6.3 South Africa
9.6.4 Other National Markets
10 Competitive Landscape
10.1 Overview of Key Vendors
10.2 New Product Launch, Partnership, Investment, and M&A
10.3 Company Profiles
  • Abbvie, Inc.
  • Acorda Therapeutics Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck KgaA
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • RELATED REPORTS

List of Tables
Table 1. Snapshot of Global Multiple Sclerosis Drugs Market in Balanced Perspective, 2020-2027
Table 2. Growth Rate of World GDP, 2020-2022
Table 3. World Health Spending by Region, $ bn, 2013-2020
Table 4. Price Comparison of Commonly Used Multiple Sclerosis Medications
Table 5. Main Adverse Effects of Multiple Sclerosis Drugs
Table 6. Main Product Trends and Market Opportunities in Global Multiple Sclerosis Drugs Market
Table 7. Global Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 8. Global Multiple Sclerosis Drugs Market: Immunomodulators by Drug, 2017-2027, $ mn
Table 9. Global Multiple Sclerosis Drugs Market: Immunosuppressants by Drug, 2017-2027, $ mn
Table 10. Global Multiple Sclerosis Drugs Market by Drug Class, 2017-2027, $ mn
Table 11. Global Multiple Sclerosis Drugs Market by Drug Category, 2017-2027, $ mn
Table 12. Global Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 13. Global Multiple Sclerosis Drugs Market by MS Type, 2017-2027, $ mn
Table 14. Global Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 15. Global Multiple Sclerosis Drugs Market by Region, 2017-2027, $ mn
Table 16. Leading National Multiple Sclerosis Drugs Market, 2020 and 2027, $ mn
Table 17. North America Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn
Table 18. U.S. Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 19. U.S. Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 20. U.S. Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 21. Canada Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 22. Canada Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 23. Canada Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 24. Mexico Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 25. Mexico Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 26. Mexico Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 27. Europe Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn
Table 28. UK Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 29. UK Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 30. UK Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 31. France Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 32. France Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 33. France Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 34. Germany Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 35. Germany Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 36. Germany Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 37. Spain Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 38. Spain Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 39. Spain Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 40. Italy Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 41. Italy Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 42. Italy Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 43. Russia Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 44. Russia Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 45. Russia Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 46. Multiple Sclerosis Drugs Market in Rest of Europe by Country, 2017-2027, $ mn
Table 47. APAC Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn
Table 48. China Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 49. China Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 50. China Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 51. Japan Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 52. Japan Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 53. Japan Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 54. India Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 55. India Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 56. India Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 57. Australia Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 58. Australia Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 59. Australia Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 60. South Korea Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 61. South Korea Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 62. South Korea Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 63. Multiple Sclerosis Drugs Market in Rest of APAC by Country/Region, 2017-2027, $ mn
Table 64. South America Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn
Table 65. Argentina Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 66. Argentina Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 67. Argentina Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 68. Brazil Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 69. Brazil Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 70. Brazil Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 71. Chile Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 72. Chile Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 73. Chile Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 74. MEA Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn
Table 75. UAE Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 76. UAE Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 77. UAE Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 78. Saudi Arabia Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 79. Saudi Arabia Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 80. Saudi Arabia Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 81. South Africa Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn
Table 82. South Africa Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn
Table 83. South Africa Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn
Table 84. Abbvie, Inc.: Company Snapshot
Table 85. Abbvie, Inc.: Business Segmentation
Table 86. Abbvie, Inc.: Product Portfolio
Table 87. Abbvie, Inc.: Revenue, 2017-2019, $ mn
List of Figures
Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027
Figure 4. Global Multiple Sclerosis Drugs Market, 2017-2027, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of Global Multiple Sclerosis Drugs Market
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060
Figure 9. Primary Restraints and Impact Factors of Global Multiple Sclerosis Drugs Market
Figure 10. Investment Opportunity Analysis
Figure 11. Porter’s Five Forces Analysis of Global Multiple Sclerosis Drugs Market
Figure 12. Breakdown of Global Multiple Sclerosis Drugs Market by Drug Type, 2020-2027, % of Revenue
Figure 13. Contribution to Global 2021-2027 Cumulative Revenue by Drug Type, Value ($ mn) and Share (%)
Figure 14. Global Multiple Sclerosis Drugs Market: Immunomodulators, 2017-2027, $ mn
Figure 15. Global Multiple Sclerosis Drugs Market: Immunosuppressants, 2017-2027, $ mn
Figure 16. Breakdown of Global Multiple Sclerosis Drugs Market by Drug Class, 2020-2027, % of Revenue
Figure 17. Contribution to Global 2021-2027 Cumulative Revenue by Drug Class, Value ($ mn) and Share (%)
Figure 18. Global Multiple Sclerosis Drugs Market: Monoclonal Antibodies, 2017-2027, $ mn
Figure 19. Global Multiple Sclerosis Drugs Market: Interferon Beta, 2017-2027, $ mn
Figure 20. Global Multiple Sclerosis Drugs Market: Sphingosine 1 Phosphate Receptor Modulators, 2017-2027, $ mn
Figure 21. Global Multiple Sclerosis Drugs Market: Mixed Polymers, 2017-2027, $ mn
Figure 22. Global Multiple Sclerosis Drugs Market: NF-?B Inhibitor, 2017-2027, $ mn
Figure 23. Global Multiple Sclerosis Drugs Market: Pyrimidine Synthesis Inhibitor, 2017-2027, $ mn
Figure 24. Global Multiple Sclerosis Drugs Market: Corticosteroids, 2017-2027, $ mn
Figure 25. Global Multiple Sclerosis Drugs Market: Adrenocorticotropic Hormone, 2017-2027, $ mn
Figure 26. Global Multiple Sclerosis Drugs Market: Other Drug Classes, 2017-2027, $ mn
Figure 27. Breakdown of Global Multiple Sclerosis Drugs Market by Drug Category, 2020-2027, % of Revenue
Figure 28. Contribution to Global 2021-2027 Cumulative Revenue by Drug Category, Value ($ mn) and Share (%)
Figure 29. Global Multiple Sclerosis Drugs Market: Large-molecule Drugs, 2017-2027, $ mn
Figure 30. Global Multiple Sclerosis Drugs Market: Small-molecule Drugs, 2017-2027, $ mn
Figure 31. Breakdown of Global Multiple Sclerosis Drugs Market by Route of Administration, 2020-2027, % of Revenue
Figure 32. Contribution to Global 2021-2027 Cumulative Revenue by Route of Administration, Value ($ mn) and Share (%)
Figure 33. Global Multiple Sclerosis Drugs Market: Oral Administration, 2017-2027, $ mn
Figure 34. Global Multiple Sclerosis Drugs Market: Parenteral Administration, 2017-2027, $ mn
Figure 35. Breakdown of Global Multiple Sclerosis Drugs Market by MS Type, 2020-2027, % of Revenue
Figure 36. Contribution to Global 2021-2027 Cumulative Revenue by MS Type, Value ($ mn) and Share (%)
Figure 37. Global Multiple Sclerosis Drugs Market: Relapsing-remitting MS (RRMS), 2017-2027, $ mn
Figure 38. Global Multiple Sclerosis Drugs Market: Primary-progressive MS (PPMS), 2017-2027, $ mn
Figure 39. Global Multiple Sclerosis Drugs Market: Secondary-progressive MS (SPMS), 2017-2027, $ mn
Figure 40. Global Multiple Sclerosis Drugs Market: Progressive-relapsing MS (PRMS), 2017-2027, $ mn
Figure 41. Breakdown of Global Multiple Sclerosis Drugs Market by Distribution Channel, 2020-2027, % of Revenue
Figure 42. Contribution to Global 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%)
Figure 43. Global Multiple Sclerosis Drugs Market: Hospital Pharmacies, 2017-2027, $ mn
Figure 44. Global Multiple Sclerosis Drugs Market: Retail Pharmacies, 2017-2027, $ mn
Figure 45. Global Multiple Sclerosis Drugs Market: Online Pharmacies, 2017-2027, $ mn
Figure 46. Global Market Snapshot by Region
Figure 47. Geographic Spread of Worldwide Multiple Sclerosis Drugs Market, 2020-2027, % of Revenue
Figure 48. Contribution to Global 2021-2027 Cumulative Revenue by Region, Value ($ mn) and Share (%)
Figure 49. North American Multiple Sclerosis Drugs Market, 2017-2027, $ mn
Figure 50. Breakdown of North America Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue
Figure 51. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 52. U.S. Multiple Sclerosis Drugs Market, 2017-2027, $ mn
Figure 53. Canada Multiple Sclerosis Drugs Market, 2017-2027, $ mn
Figure 54. Multiple Sclerosis Drugs Market in Mexico, 2017-2027, $ mn
Figure 55. European Multiple Sclerosis Drugs Market, 2017-2027, $ mn
Figure 56. Breakdown of European Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue
Figure 57. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 58. Multiple Sclerosis Drugs Market in UK, 2017-2027, $ mn
Figure 59. Multiple Sclerosis Drugs Market in France, 2017-2027, $ mn
Figure 60. Multiple Sclerosis Drugs Market in Germany, 2017-2027, $ mn
Figure 61. Multiple Sclerosis Drugs Market in Spain, 2017-2027, $ mn
Figure 62. Multiple Sclerosis Drugs Market in Italy, 2017-2027, $ mn
Figure 63. Multiple Sclerosis Drugs Market in Russia, 2017-2027, $ mn
Figure 64. Multiple Sclerosis Drugs Market in Rest of Europe, 2017-2027, $ mn
Figure 65. Asia-Pacific Multiple Sclerosis Drugs Market, 2017-2027, $ mn
Figure 66. Breakdown of APAC Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue
Figure 67. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 68. Multiple Sclerosis Drugs Market in China, 2017-2027, $ mn
Figure 69. Multiple Sclerosis Drugs Market in Japan, 2017-2027, $ mn
Figure 70. Multiple Sclerosis Drugs Market in India, 2017-2027, $ mn
Figure 71. Multiple Sclerosis Drugs Market in Australia, 2017-2027, $ mn
Figure 72. Multiple Sclerosis Drugs Market in South Korea, 2017-2027, $ mn
Figure 73. Multiple Sclerosis Drugs Market in Rest of APAC, 2017-2027, $ mn
Figure 74. South America Multiple Sclerosis Drugs Market, 2017-2027, $ mn
Figure 75. Breakdown of South America Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue
Figure 76. Contribution to South America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 77. Multiple Sclerosis Drugs Market in Argentina, 2017-2027, $ mn
Figure 78. Multiple Sclerosis Drugs Market in Brazil, 2017-2027, $ mn
Figure 79. Multiple Sclerosis Drugs Market in Chile, 2017-2027, $ mn
Figure 80. Multiple Sclerosis Drugs Market in Rest of South America, 2017-2027, $ mn
Figure 81. Multiple Sclerosis Drugs Market in Middle East and Africa (MEA), 2017-2027, $ mn
Figure 82. Breakdown of MEA Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue
Figure 83. Contribution to MEA 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 84. Multiple Sclerosis Drugs Market in UAE, 2017-2027, $ mn
Figure 85. Multiple Sclerosis Drugs Market in Saudi Arabia, 2017-2027, $ mn
Figure 86. Multiple Sclerosis Drugs Market in South Africa, 2017-2027, $ mn
Figure 87. Growth Stage of Global Multiple Sclerosis Drugs Industry over the Forecast Period
Note: Product cover images may vary from those shown
  • Abbvie, Inc.
  • Acorda Therapeutics Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck KgaA
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)


Note: Product cover images may vary from those shown

Loading
LOADING...